Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Obstetricia y Ginecología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 12 de feb de 2008
ID: NCT00567190
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
INTERVENTIONAL
Inicio: 1 de jul de 2021
ID: NCT04906395
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as Adjuvant Therapy
INTERVENTIONAL
Inicio: 1 de may de 2003
ID: NCT00171340
Completado
ClinicalTrials.gov
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum
OBSERVATIONAL
Inicio: 9 de jun de 2003
ID: NCT00042289
Completado
Fase 3
ClinicalTrials.gov
A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma
INTERVENTIONAL
Inicio: 1 de sept de 1998
ID: NCT00003636
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
INTERVENTIONAL
Inicio: 22 de feb de 2021
ID: NCT04697628
Completado
Fase 3
ClinicalTrials.gov
A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy
INTERVENTIONAL
Inicio: 1 de nov de 2001
ID: NCT00045032
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
INTERVENTIONAL
Inicio: 3 de abr de 2013
ID: NCT01772472
Completado
ClinicalTrials.gov
Clinical and Immunologic Impact of SARS-CoV-2 in Hospitalized Pregnant Women and Neonates in Argentina
OBSERVATIONAL
Inicio: 10 de jul de 2020
ID: NCT04362956
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)
INTERVENTIONAL
Inicio: 27 de nov de 2024
ID: NCT06428396
Completado
Fase 3
ClinicalTrials.gov
Randomized Double-Blind Trial In Postmenopausal Women With Primary Breast Cancer Who Have Received Adjuvant Tamoxifen For 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment With Further Tamoxifen
INTERVENTIONAL
Inicio: 1 de feb de 1998
ID: NCT00038467
Terminado
Fase 3
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)
INTERVENTIONAL
Inicio: 2 de jun de 2010
ID: NCT01077154
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
INTERVENTIONAL
Inicio: 14 de jun de 2018
ID: NCT03493854
Activo, no recluta
ClinicalTrials.gov
Real World Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy Against RSV Illness in Infants
OBSERVATIONAL
Inicio: 26 de ago de 2024
ID: NCT06647654
Completado
Fase 3
ClinicalTrials.gov
Treatment of Postpartum Hemorrhage With Misoprostol: Who do we Treat? Who Will Develop Fever?
INTERVENTIONAL
Inicio: 1 de sept de 2015
ID: NCT02163616
Reclutando
Fase 3
ClinicalTrials.gov
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
INTERVENTIONAL
Inicio: 15 de mar de 2023
ID: NCT05445778
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
INTERVENTIONAL
Inicio: 23 de nov de 2023
ID: NCT06103864
Completado
Fase 3
ClinicalTrials.gov
a Phase 3 Randomized Double Blind Evaluation of LY353381 Compared With Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
INTERVENTIONAL
ID: NCT00034125
Completado
Fase 2
ClinicalTrials.gov
An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer
INTERVENTIONAL
Inicio: 7 de mar de 2013
ID: NCT01698918
Completado
ClinicalTrials.gov
Multicentre NIS Retrospective Study to Know the Prevalence of HER2- Low,Clinical Characteristics,Treatment Patterns,Associated Outcome in Patient With HER2-negative in Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy
OBSERVATIONAL
Inicio: 23 de abr de 2024
ID: NCT06131424
Anterior
1
...
17
18
19
...
434
Siguiente
Filtros